Farmers & Merchants Investments Inc. Sells 7,202 Shares of Pfizer Inc. (NYSE:PFE)

Farmers & Merchants Investments Inc. cut its holdings in Pfizer Inc. (NYSE:PFE) by 3.5% in the 4th quarter, Holdings Channel.com reports. The firm owned 200,710 shares of the biopharmaceutical company’s stock after selling 7,202 shares during the quarter. Farmers & Merchants Investments Inc.’s holdings in Pfizer were worth $5,325,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in PFE. Brookstone Capital Management boosted its position in Pfizer by 1.5% during the 3rd quarter. Brookstone Capital Management now owns 123,930 shares of the biopharmaceutical company’s stock worth $3,587,000 after acquiring an additional 1,876 shares during the last quarter. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors boosted its stake in shares of Pfizer by 25.4% during the 3rd quarter. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors now owns 12,223 shares of the biopharmaceutical company’s stock worth $354,000 after buying an additional 2,479 shares during the last quarter. Wedmont Private Capital grew its holdings in shares of Pfizer by 5.6% in the 3rd quarter. Wedmont Private Capital now owns 37,473 shares of the biopharmaceutical company’s stock valued at $1,094,000 after acquiring an additional 1,994 shares in the last quarter. Quotient Wealth Partners LLC boosted its holdings in shares of Pfizer by 26.8% in the 3rd quarter. Quotient Wealth Partners LLC now owns 10,267 shares of the biopharmaceutical company’s stock valued at $297,000 after buying an additional 2,172 shares during the last quarter. Finally, PPS&V Asset Management Consultants Inc. grew its stake in shares of Pfizer by 7.2% in the third quarter. PPS&V Asset Management Consultants Inc. now owns 14,394 shares of the biopharmaceutical company’s stock valued at $417,000 after buying an additional 963 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages have commented on PFE. Bank of America reiterated a “neutral” rating and issued a $29.00 price target on shares of Pfizer in a research note on Tuesday, December 10th. Citigroup lowered their price target on Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 28th. UBS Group cut their price objective on Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research report on Wednesday, January 8th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a research report on Wednesday, October 23rd. Finally, Guggenheim lowered their price target on shares of Pfizer from $35.00 to $33.00 and set a “buy” rating on the stock in a report on Wednesday, December 11th. One analyst has rated the stock with a sell rating, eight have given a hold rating, six have assigned a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, Pfizer presently has a consensus rating of “Moderate Buy” and an average price target of $31.92.

Pfizer Price Performance

Shares of NYSE:PFE opened at $25.76 on Friday. The company has a market cap of $145.96 billion, a price-to-earnings ratio of 18.27, a PEG ratio of 0.64 and a beta of 0.64. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The firm has a 50 day simple moving average of $26.28 and a 200 day simple moving average of $27.74. Pfizer Inc. has a one year low of $24.48 and a one year high of $31.54.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, topping analysts’ consensus estimates of $0.48 by $0.15. The firm had revenue of $17.76 billion for the quarter, compared to analyst estimates of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company’s revenue for the quarter was up 24.7% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.10 EPS. Research analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be paid a $0.43 dividend. This is a boost from Pfizer’s previous quarterly dividend of $0.42. The ex-dividend date is Friday, January 24th. This represents a $1.72 annualized dividend and a dividend yield of 6.68%. Pfizer’s dividend payout ratio is presently 121.99%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.